• CLINIMARK: GOOD BIOMARKER PRACTICE TO INCREASE THE NUMBER OF CLINICALLY VALIDATED BIOMARKERS.

    CLINIMARK: GOOD BIOMARKER PRACTICE TO INCREASE THE NUMBER OF CLINICALLY VALIDATED BIOMARKERS.

  • THE AIM OF THE CLINIMARK NETWORK IS TO ESTABLISH A ‘BEST BIOMARKER PRACTICE’ COMMUNITY TO SIGNIFICANTLY INCREASE THE NUMBER OF BIOMARKERS WITH REPRODUCIBLY DEMONSTRATED FEASIBILITY.

    THE AIM OF THE CLINIMARK NETWORK IS TO ESTABLISH A ‘BEST BIOMARKER PRACTICE’ COMMUNITY TO SIGNIFICANTLY INCREASE THE NUMBER OF BIOMARKERS WITH REPRODUCIBLY DEMONSTRATED FEASIBILITY.

  • IMPROVING THE PIPELINE FROM BIOMARKER RESEARCH TO MARKET

    IMPROVING THE PIPELINE FROM BIOMARKER RESEARCH TO MARKET

  • THE CLINIMARK NETWORK WILL FOCUS ON THE ANALYTICAL AND CLINICAL  VALIDATION OF BIOMARKERS TO IMPROVE THE TRANSITION OF BIOMARKERS FROM THE RESEARCH TO THE MARKET PHASE

    THE CLINIMARK NETWORK WILL FOCUS ON THE ANALYTICAL AND CLINICAL VALIDATION OF BIOMARKERS TO IMPROVE THE TRANSITION OF BIOMARKERS FROM THE RESEARCH TO THE MARKET PHASE

COST Association COST Action CA16113

THE AIM OF THE CLINIMARK NETWORK IS TO ESTABLISH A ‘BEST BIOMARKER PRACTICE’ COMMUNITY TO SIGNIFICANTLY INCREASE THE NUMBER OF BIOMARKERS WITH REPRODUCIBLY DEMONSTRATED FEASIBILITY.
Thousands of circulating proteins have been shown to be hallmarks of emerging disease, response to treatment, or a patients’ prognosis. The identification of these small molecule biomarkers holds a great promise for significant improvement of personalized medicine based on simple blood tests.
For instance, diagnosis and prognosis with biomarkers (e.g. carcinoembryonic antigen (CEA)) has significantly improved patient survival and decreased healthcare costs in colorectal cancer patients. Unfortunately, despite significant investments to increase the number of biomarker studies, only ~150 out of thousands of identified biomarkers have currently been implemented in clinical practice.

Action details

Memorandum of Understanding

112/16

CSO Approval date

24/10/2016

Start of Action

14/03/2017

End of Action

13/03/2021

Research Outputs

Updates on the research outputs of CliniMARK are provided on this page.

International peer-reviewed journal articles

CliniMARK working papers

Related publications

Management Committee & Working Group Leaders

News & Events

CliniMark CostAction Meeting
September 20th - 22th 2018, Belgrade - Serbia

Don´t miss this calls

Understanding causative mechanisms in co- and multimorbidities
Publication date: 27 October 2017
Types of action: RIA Research and Innovation action
Deadline Model: two-stage
Planed opening: 26 July 2018

Systems approaches for the discovery of combinatorial therapies for complex disorders
Publication date: 27 October 2017
Types of action: RIA Research and Innovation action
Deadline Model: two-stage
Planed opening: 26 July 2018
(Posted on 23 July 2018)

CliniMark CostAction Meeting
March 12th - 15th 2018, Cascais - Portugal

ROBoCoP: a Respiratory disease Occupational Biomonitoring Collaborative Project

Chronic obstructive pulmonary disease (COPD) is a major public health problem with a prevalence in Switzerland reaching 15.9% in men. Exposure to particulate matter (PM) is a known COPD risk factor via oxidative stress pathway. Reactive oxygen species (ROS) and their metabolites could be predictive to COPD onset and be used as diagnostic biomarkers.
ROBoCop project, in the framework of CliniMark EU-COST Action, aims to select and validate a panel of oxidative stress biomarkers analyzed in non-invasive biological samples.
(Posted on 11 January 2018)

Conference Validation of biomarkers
October 6th 2017, De Doelen - ICC Rotterdam

Translating biomarker candidates from discovery to the clinic remains a challenge. This conference examines how integrated technologies can bridge the innovation gap.

Waters MS Technology Days 2017: Evaluation of biomarkers predictive for Alzheimer's disease

During the Waters MS Technology Days 2017 in Basel (6/27) and Lausanne (6/27) research results were presented from a BDC study carried out in the group of Dr. Theo Luider at the Erasmus MC (Rotterdam) about development and application of an LC-MS assay to evaluate Pregnancy Zone Protein as potential biomarker for the prediction of Alzheimer's disease. Information about the meeting here.
(Posted on 24 August 2017)

EATRIS Conference, Prague, September 24-26, 2017

EATRIS, the European Infrastructure for Translational Medicine in which the BDC laboratories of profs Bischoff, Luider and van Gool are members, will hold its annual Translational Conference in Prague, September 24-26. Conference information here.
(Posted 17 May 2017)

Bridging the translational innovation gap through good biomarker practice

In collaboration with the European technology infrastructures EATRIS, BBMRI and ELIXIR, prof van Gool and other scientists from the Biomarker Development Center published a comment in Nature Reviews Drug Discovery to join efforts in defining the Good Biomarker Principle guidelines that will support successful biomarker discovery and development activities. These guidelines will be defined in the COST action CliniMARK, initiated and coordinated by dr Luider of the BDC. See comment here.
(Posted 10 May 2017)

CliniMARK Kick-off meeting

The CliniMARK network has the goal of establishing "Best Biomarker Practice" (BBP) guidelines to radically improve the process from biomarker discovery to clinical use. The kick-off meeting was held at the COST offices in Brussels on March 14, 2017. A plan was developed to define BBP guidelines and to apply these guidelines for the validation of biomarkers with COPD as an example. The next meeting will be held from October 5 to 7, 2017, at the Erasmus MC (Rotterdam) in conjunction with the Biomarker Symposium. For further information please contact This email address is being protected from spambots. You need JavaScript enabled to view it..
(Posted 20 March 2017)